What are GLP-1 medications and why are they in demand?
GLP-1 receptor agonists are a class of medications that activate glucagon-like peptide-1 receptors in the brain, pancreas, and GI tract. They reduce appetite by acting on hypothalamic satiety centers, slow gastric emptying to prolong fullness, and regulate insulin and glucagon secretion in a glucose-dependent manner.
The most prominent GLP-1 medications relevant to this discussion are:
- Ozempic (semaglutide injection, FDA-approved for type 2 diabetes management)
- Wegovy (semaglutide injection at higher dose, FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition)
- Mounjaro / Zepbound (tirzepatide, FDA-approved for type 2 diabetes and chronic weight management respectively)
Demand has outpaced supply and insurance capacity. The result: many patients who could benefit clinically are navigating a coverage gap between what their clinician recommends and what their insurance will pay for.
Does Tricare cover semaglutide or tirzepatide?
Tricare coverage for GLP-1 medications as of 2024-2025 follows a pattern common across many government and commercial insurers: better for diabetes indications, limited or absent for weight management only.
| Drug | Indication | Tricare coverage (2024–2025) |
|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | Better prospects with T2D diagnosis + PA |
| Wegovy (semaglutide) | Weight management | Generally not covered for obesity alone |
| Mounjaro (tirzepatide) | Type 2 diabetes | Coverage pathway exists with T2D diagnosis + PA |
| Zepbound (tirzepatide) | Weight management | Same weight-management coverage gap as Wegovy |
Weight management indication
Tricare generally does not cover Wegovy or other GLP-1 medications specifically for chronic weight management without a co-occurring qualifying diagnosis. Obesity alone, without an associated diagnosis like type 2 diabetes, has historically been excluded from formulary coverage for this drug class under Tricare. This mirrors broader public and commercial insurance patterns — despite the clinical evidence supporting GLP-1s for weight outcomes, obesity-as-primary-indication coverage remains limited across most plans.
Type 2 diabetes indication
Ozempic (and other GLP-1 drugs labeled for type 2 diabetes) has better coverage prospects under Tricare when prescribed for an active type 2 diabetes diagnosis with appropriate billing codes. Prior authorization is typically still required, and criteria vary by Tricare plan variant (Prime vs. Select vs. Reserve Select vs. retired beneficiary status).
Important caveat: prescribing a diabetes medication for weight management in a patient without diabetes is off-label use. Coverage for off-label prescribing is generally not available under Tricare formulary policies.
Tirzepatide (Mounjaro / Zepbound)
Tirzepatide follows a similar pattern: Mounjaro (diabetes indication) may have coverage pathways for type 2 diabetes; Zepbound (weight management indication) faces the same weight-management coverage gap as Wegovy under Tricare.
Verify your current coverage directly
Formulary status changes. The Defense Health Agency updates Tricare formulary policies, and legislative pressure to expand coverage for obesity medications has been ongoing. Before assuming coverage or non-coverage, check the TRICARE Formulary Search at formulary.tricare.mil and contact Tricare directly with your specific plan details and the NDC or drug name in question.
Under Tricare the indication is everything: a GLP-1 prescribed for type 2 diabetes has a coverage path; the same drug for weight loss alone usually does not.
What does Tricare prior authorization for GLP-1 require?
Even where a GLP-1 medication is formulary-covered under Tricare, prior authorization (PA) is almost universally required. PA for GLP-1 medications under government and commercial insurers typically requires:
- A qualifying diagnosis: Type 2 diabetes for Ozempic/Mounjaro; obesity (BMI ≥30, or ≥27 with a qualifying comorbidity) for Wegovy/Zepbound, where covered.
- Documentation of prior weight-management attempts: Many PA criteria require documented evidence that lifestyle interventions, dietary modification, or other approved approaches have been tried and have not achieved adequate response.
- Prescriber documentation: A licensed physician or NP must attest to the clinical rationale and submit supporting clinical notes.
- Step therapy requirements: Some plans require trial of an older, lower-cost weight-management medication before approving a GLP-1 agent.
Your MTF (Military Treatment Facility) primary care manager or a Tricare-accepting civilian prescriber can initiate a prior authorization request if you have a qualifying diagnosis. The PA process is not automatic and typically takes 1-2 weeks.
What are my options when Tricare doesn’t cover GLP-1 medications?
If Tricare does not cover your GLP-1 medication, several pathways are available:
Manufacturer savings programs
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) offer savings cards and patient assistance programs for commercially insured patients. However, these programs often explicitly exclude patients with government insurance (Medicare, Medicaid, Tricare). Read the program terms carefully — most manufacturer coupons are not available to Tricare beneficiaries.
Compounded semaglutide or tirzepatide
Compounded GLP-1 medications — semaglutide or tirzepatide prepared by licensed 503A compounding pharmacies in the USA — are a clinically supervised option for patients whose insurance does not cover branded GLP-1 drugs. The preparation is compounded rather than manufactured — it is not a generic and is not interchangeable with Ozempic or Wegovy — requires a valid clinician prescription, and is typically significantly less expensive than branded alternatives at retail.
Important caveats about compounded GLP-1s:
- Compounded semaglutide is not FDA-approved and is not interchangeable with Ozempic or Wegovy.
- It is not a generic. It is a separately compounded preparation that requires a valid prescription.
- The regulatory landscape for compounded GLP-1s has been evolving with the semaglutide shortage designation. Work with a licensed telehealth provider that stays current on the legal status.
- PepScribe’s standard: compounded by licensed USA 503A pharmacies only. No hidden overseas supply chain.
Appeal a coverage denial
If Tricare denies prior authorization, you have the right to appeal. A formal appeal requires documentation from your prescribing clinician explaining the medical necessity and why the clinical situation warrants the requested medication. Appeals are not always successful, but they are the appropriate channel when a denial appears to be based on a formulary rule rather than a clinical judgment.
What does GLP-1 cost without insurance?
Branded GLP-1 medications at retail cost can exceed $1,000/month without insurance or manufacturer programs. This is a significant barrier for patients who would benefit clinically. The cost has driven substantial growth in the compounded semaglutide market, which can provide clinician-supervised therapy at lower out-of-pocket cost through licensed USA pharmacies.
A clinician-supervised program that includes an intake assessment, prescription, and follow-up monitoring is the appropriate framework regardless of which formulation you pursue. Self-procuring GLP-1 medications from unregulated sources — online vendors, gray-market suppliers, or overseas pharmacies — carries meaningful risks related to purity, sterility, accurate dosing, and no legitimate prescribing oversight.
Frequently asked questions
Does Tricare cover Wegovy or Ozempic for weight loss?
As of 2024-2025, Tricare generally does not cover GLP-1 medications (Wegovy, Saxenda) for weight management alone. Ozempic may be covered for type 2 diabetes management with appropriate diagnosis codes. Coverage policies evolve — check the TRICARE formulary search tool (formulary.tricare.mil) and your specific TRICARE plan for the most current status.
Does Tricare cover semaglutide for diabetes?
Ozempic (brand semaglutide for type 2 diabetes) has better coverage prospects under Tricare when prescribed for type 2 diabetes with appropriate diagnosis. It is not typically covered for weight management only. Coverage tiers and prior authorization requirements vary by TRICARE plan (Prime, Select, Reserve Select).
Is compounded semaglutide covered by Tricare?
Compounded medications are generally not covered by Tricare, which requires FDA-approved products on the formulary. Compounded semaglutide is a separate preparation from branded Ozempic/Wegovy and does not carry those drugs' approvals. It is typically an out-of-pocket expense.
What does GLP-1 medication typically cost without insurance?
Branded GLP-1 medications (Wegovy, Ozempic) can cost $900-$1,400/month without insurance or manufacturer coupons. Clinician-supervised compounded semaglutide from licensed USA 503A pharmacies is typically significantly less expensive — the range varies by dose and provider. PepScribe clinicians can review your situation and discuss options.
Are there prior authorization requirements for GLP-1 coverage with Tricare?
Even where GLP-1 medications are formulary-covered by Tricare, prior authorization is typically required. This usually involves documentation of a qualifying diagnosis (type 2 diabetes, or in some cases obesity with comorbidities), a physician's attestation that other weight-management approaches have been tried, and BMI thresholds. Requirements vary by plan and are subject to change.